136
Participants
Start Date
January 14, 2013
Primary Completion Date
March 1, 2027
Study Completion Date
July 1, 2027
EBV-specific T cells: A
Patients may receive cells with or without lymphodepletion. Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
EBV-specific T cells: B
Patients may receive cells with or without lymphodepletion. Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
NOT_YET_RECRUITING
Harris Health System (includes ben Taub General Hospital and Smith), Houston
RECRUITING
Houston Methodist Hospital, Houston
RECRUITING
Texas Children's Hospital, Houston
The Methodist Hospital Research Institute
OTHER
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
National Institutes of Health (NIH)
NIH
National Cancer Institute (NCI)
NIH
Harris County Hospital District
OTHER_GOV
Baylor College of Medicine
OTHER